Differential qualitative responses to rivastigmine in APOE E4 carriers and noncarriers

Pharmacogenomics Journal

Volumn 4, Issue 5, 2004, Pages 332-335

  Farlow, M ^a   Lane, R ^b   Kudaravalli, S ^b   He, Y ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Apolipoprotein E; Rivastigmine

Indexed keywords

APOLIPOPROTEIN E4; PLACEBO; RIVASTIGMINE;

AGED; ALLELE; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANOREXIA; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; DOUBLE-BLIND METHOD; FEMALE; HETEROZYGOTE DETECTION; HUMANS; MALE; MULTICENTER STUDIES; PHENYLCARBAMATES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 5044252173     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500267     Document Type: Article

References (16)

1. Schumock GT. Economic considerations in the treatment and management of Alzheimer's disease. Am J Health Syst Pharm 1998; 55(Suppl 2): S17-521.
2. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001; 32: 181-184.
3. Cedazo-Minguez A, Cowburn RF. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mold Med 2001; 5: 254-266.
4. Richard F, Amouyel P. Genetic susceptibility factors for Alzheimer's disease. Eur J Pharmacol 2001; 412: 1-12.
5. Hiltunen M, Mannermaa A, Thompson D, Easton D, Pirskanen M, Helisalmi S et al. Genome-wide linkage disequilibrium mapping of late-onset Alzheimer's disease in Finland. Neurology 2001; 57: 1663-1668.
6. Bickeböller H, Campion D, Brice A, Amouyel P, Hannequin D, Didierjean O et al. Apolipoprotein E and Alzheimeir disease: genotype-specific risks by age and sex. Am J Hum Genet 1997; 60: 439-446.
7. Rubinsztein DC, Easton DF. Apolipoprotein E genetic variation and Alzheimer's disease. A meta-analysis. Dement Geriatr Cogn Disord 1999; 10: 199-209.
8. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
9. Lehmann DJ, Williams J, McBroom J, Smith AD. Using meta-analysis to explain the diversity of results in genetic studies of late onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience 2001; 108: 541-554.
10. Lendon CL. Determinant of response to anticholinesterase therapy in the treatment of Alzheimer's disease. Poster presented at the 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden, 20-25 July 2002.
11. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
12. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999; 318: 633-638.
13. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12: 69-77.
14. Raskind MA, Peskind ER, Wessel T, Yuan W, the Galantamine USA-1 Study Group. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-2268.
15. Wilcock GK, Lilienfeld S, Gaens E on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. BMJ 2000; 321: 1-7.
16. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 1998; 50: 669-677.